## Masahiro Fujita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/994851/publications.pdf

Version: 2024-02-01

118 papers

8,467 citations

45 h-index 89 g-index

120 all docs

120 docs citations

120 times ranked 7219 citing authors

#	Article	IF	CITATIONS
1	Alterations in brain synaptic proteins and mRNAs in mood disorders: a systematic review and meta-analysis of postmortem brain studies. Molecular Psychiatry, 2022, 27, 1362-1372.	7.9	6
2	Imaging Neuroinflammation in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 45S-52S.	5.0	22
3	Neuroinflammation is highest in areas of disease progression in semantic dementia. Brain, 2021, 144, 1565-1575.	7.6	23
4	In vitro and pilot in vivo imaging of 18ÂkDa translocator protein (TSPO) in inflammatory vascular disease. EJNMMI Research, 2021, 11, 45.	2.5	9
5	PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. Journal of Neuroinflammation, 2020, 17, 140.	7.2	35
6	First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3143-3151.	6.4	27
7	PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune–Albright Syndrome, a Genetic Mosaic Disorder. Journal of Nuclear Medicine, 2020, 61, 1672-1677.	5.0	6
8	Discovery, Radiolabeling, and Evaluation of Subtype-Selective Inhibitors for Positron Emission Tomography Imaging of Brain Phosphodiesterase-4D. ACS Chemical Neuroscience, 2020, 11, 1311-1323.	3.5	12
9	PET/CT for Neuroinflammation. , 2020, , 217-228.		1
10	Building a database for brain 18 kDa translocator protein imaged using [ <sup>11</sup> C]PBR28 in healthy subjects. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1138-1147.	4.3	16
11	Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison 11C-choline and FDG PET/CT with dynamic contrast-enhanced CT. Japanese Journal of Radiology, 2019, 37, 165-177.	2.4	11
12	[11C](R)-Rolipram positron emission tomography detects DISC1 inhibition of phosphodiesterase type 4 in live Disc1 locus-impaired mice. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1306-1313.	4.3	3
13	<sup>11</sup> C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than <sup>11</sup> C-( <i>R</i> )-PK11195. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 393-403.	4.3	51
14	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Research, 2018, 8, 57.	2.5	144
15	Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST. Annals of Nuclear Medicine, 2018, 32, 453-462.	2.2	6
16	Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys. Journal of Nuclear Medicine, 2018, 59, 1907-1912.	5.0	43
17	3-Substituted 1,5-Diaryl-1 <i>H</i> -1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [ $<$ sup>11 <math >11C]PS13 for Quantitative Imaging. ACS Chemical Neuroscience, 2018, 9, 2620-2627.	3.5	24
18	<sup>11</sup> C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. Journal of Nuclear Medicine, 2017, 58, 320-325.	5.0	146

#	Article	IF	CITATIONS
19	Comparison of two PET radioligands, [11C]FPEB and [11C]SP203, for quantification of metabotropic glutamate receptor 5 in human brain. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 2458-2470.	4.3	21
20	Comparison of four 11C-labeled PET ligands to quantify translocator protein 18ÂkDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176—based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Research, 2017, 7, 84.	2.5	80
21	The PET Radioligand <sup>18</sup> F-FIMX Images and Quantifies Metabotropic Glutamate Receptor 1 in Proportion to the Regional Density of Its Gene Transcript in Human Brain. Journal of Nuclear Medicine, 2016, 57, 242-247.	5.0	32
22	Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 326-339.	4.3	36
23	Neuroinflammation in Temporal Lobe Epilepsy Measured Using Positron Emission Tomographic Imaging of Translocator Protein. JAMA Neurology, 2015, 72, 882.	9.0	126
24	Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. Journal of Nuclear Medicine, 2015, 56, 701-706.	5.0	183
25	Improved Models for Plasma Radiometabolite Correction and their Impact on Kinetic Quantification in PET Studies. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1462-1469.	4.3	14
26	Evaluation in monkey of two candidate PET radioligands, [ <sup>11</sup> C]RXâ€1 and [ <sup>18</sup> F]RXâ€2, for imaging brain 5â€HT <sub>4</sub> receptors. Synapse, 2014, 68, 613-623.	1.2	8
27	Application of calibrated image-derived input function to a clinical protocol. Nuclear Medicine Communications, 2014, 35, 1188-1189.	1.1	1
28	Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. NeuroImage, 2014, 87, 89-95.	4.2	29
29	Synthesis and Evaluation of Translocator 18 kDa Protein (TSPO) Positron Emission Tomography (PET) Radioligands with Low Binding Sensitivity to Human Single Nucleotide Polymorphism rs6971. ACS Chemical Neuroscience, 2014, 5, 963-971.	3.5	91
30	Synthesis and evaluation of candidate PET radioligands for corticotropin-releasing factor type-1 receptors. Nuclear Medicine and Biology, 2014, 41, 524-535.	0.6	14
31	In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. Neurolmage, 2014, 84, 733-741.	4.2	29
32	Image-Derived Input Function Derived from a Supervised Clustering Algorithm: Methodology and Validation in a Clinical Protocol Using $[11C](R)$ -Rolipram. PLoS ONE, 2014, 9, e89101.	2.5	13
33	Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. Molecular Autism, 2013, 4, 15.	4.9	50
34	Propofol Decreases In Vivo Binding of $\sup 11 < \sup C$ -PBR28 to Translocator Protein (18 kDa) in the Human Brain. Journal of Nuclear Medicine, 2013, 54, 64-69.	5.0	30
35	PET Reveals Inflammation around Calcified Taenia solium Granulomas with Perilesional Edema. PLoS ONE, 2013, 8, e74052.	2.5	41
36	Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand <sup>11</sup> C-NOP-1A. Journal of Nuclear Medicine, 2012, 53, 385-392.	5.0	65

#	Article	IF	CITATIONS
37	Increased In Vivo Expression of an Inflammatory Marker in Temporal Lobe Epilepsy. Journal of Nuclear Medicine, 2012, 53, 234-240.	5.0	90
38	Image-derived input function in PET brain studies. Nuclear Medicine Communications, 2012, 33, 982-989.	1.1	14
39	Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder. Biological Psychiatry, 2012, 72, 548-554.	1.3	60
40	Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using 18F-SP203. Neurolmage, 2012, 59, 2124-2130.	4.2	13
41	Population-based input function and image-derived input function for [11C](R)-rolipram PET imaging: Methodology, validation and application to the study of major depressive disorder. Neurolmage, 2012, 63, 1532-1541.	4.2	50
42	Synthesis and Evaluation of Radioligands for Imaging Brain Nociceptin/Orphanin FQ Peptide (NOP) Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2011, 54, 2687-2700.	6.4	62
43	Evaluation of Novel <i>N</i> <sup>1</sup> -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. Journal of Medicinal Chemistry, 2011, 54, 366-373.	6.4	25
44	Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: A retest study and use of an image-derived input function. Neurolmage, 2011, 54, 1903-1909.	4.2	36
45	Comparison of 18F- and 11C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 352-357.	6.4	33
46	Translocator Protein PET Imaging for Glial Activation in Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2011, 6, 354-361.	4.1	98
47	Brain and Whole-Body Imaging in Rhesus Monkeys of <sup>11</sup> C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors. Journal of Nuclear Medicine, 2011, 52, 1638-1645.	5.0	50
48	Image-Derived Input Function for Brain PET Studies: Many Challenges and Few Opportunities. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1986-1998.	4.3	246
49	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. Journal of Nuclear Medicine, 2011, 52, 24-32.	5.0	330
50	Image-Derived Input Function for Human Brain Using High Resolution PET Imaging with [11C](R)-rolipram and [11C]PBR28. PLoS ONE, 2011, 6, e17056.	2.5	40
51	Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1943-1949.	6.4	32
52	[ <i>carbonyl</i> â€ <sup>11</sup> C]Benzyl acetate: Automated radiosynthesis via Pdâ€mediated [ <sup>11</sup> C]carbon monoxide chemistry and PET measurement of brain uptake in monkey. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 548-551.	1.0	28
53	Effects of cAMPâ€dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats. Synapse, 2010, 64, 172-176.	1.2	17
54	In vivo binding of protoporphyrin IX to rat translocator protein imaged with positron emission tomography. Synapse, 2010, 64, 649-653.	1.2	9

#	Article	lF	Citations
55	Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, <sup>18</sup> F-PBR06, to Image Translocator Protein (18 kDa). Journal of Nuclear Medicine, 2010, 51, 145-149.	5.0	42
56	Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage, 2010, 49, 2924-2932.	4.2	237
57	Stroke Incidentally Identified Using Improved Positron Emission Tomography for Microglial Activation. Archives of Neurology, 2009, 66, 1288-9.	4.5	21
58	PET Measurement of the In Vivo Affinity of $<$ sup $>$ 11 $<$ sup $>$ C- $(<$ i $>$ R $<$ $ $ i $>$ )-Rolipram and the Density of Its Target, Phosphodiesterase-4, in the Brains of Conscious and Anesthetized Rats. Journal of Nuclear Medicine, 2009, 50, 749-756.	5.0	31
59	Quantification of Translocator Protein (18 kDa) in the Human Brain with PET and a Novel Radioligand, <sup>18</sup> F-PBR06. Journal of Nuclear Medicine, 2009, 50, 1047-1053.	5.0	75
60	Single-Step High-Yield Radiosynthesis and Evaluation of a Sensitive <sup>18</sup> F-Labeled Ligand for Imaging Brain Peripheral Benzodiazepine Receptors with PET. Journal of Medicinal Chemistry, 2009, 52, 688-699.	6.4	85
61	Small effect of dopamine release and no effect of dopamine depletion on [ <sup>18</sup> F]fallypride binding in healthy humans. Synapse, 2008, 62, 399-408.	1.2	104
62	Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with $[11C]$ NNC $112$ and $[18F]$ FDOPA. Psychiatry Research - Neuroimaging, 2008, 163, 171-182.	1.8	102
63	Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [11C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses. Nuclear Medicine and Biology, 2008, 35, 493-500.	0.6	18
64	Synthesis and Evaluation in Monkey of Two Sensitive $\sup 11 <  \sup > C$ -Labeled Aryloxyanilide Ligands for Imaging Brain Peripheral Benzodiazepine Receptors In Vivo. Journal of Medicinal Chemistry, 2008, 51, 17-30.	6.4	178
65	Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neurolmage, 2008, 39, 1289-1298.	4.2	126
66	Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. NeuroImage, 2008, 40, 43-52.	4.2	193
67	Kinetic analysis in healthy humans of $[11C]$ PBR28, a new positron emission tomography radioligand to image the peripheral benzodiazepine receptor. Neurolmage, 2008, 41, T34.	4.2	0
68	Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: An autoradiographic study with [3H]PK 11195. Atherosclerosis, 2008, 201, 108-111.	0.8	61
69	Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET. Journal of Nuclear Medicine, 2008, 49, 2042-2048.	5.0	57
70	Radiation Dosimetry and Biodistribution in Monkey and Man of 11C-PBR28: A PET Radioligand to Image Inflammation. Journal of Nuclear Medicine, 2007, 48, 2072-2079.	5.0	136
71	Disulfiram Inhibits Defluorination of 18F-FCWAY, Reduces Bone Radioactivity, and Enhances Visualization of Radioligand Binding to Serotonin 5-HT1A Receptors in Human Brain. Journal of Nuclear Medicine, 2007, 48, 1154-1161.	5.0	52
72	PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neuroscience Letters, 2007, 411, 200-205.	2.1	158

#	Article	IF	Citations
73	In vivo and in vitro measurement of brain phosphodiesterase 4 in rats after antidepressant administration. Synapse, 2007, 61, 78-86.	1.2	19
74	Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain. Synapse, 2007, 61, 595-605.	1.2	68
75	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1533-1539.	4.3	1,840
76	PET [11C]DASB Imaging of Serotonin Transporters in Patients with Alcoholism. Alcoholism: Clinical and Experimental Research, 2007, 31, 28-32.	2.4	55
77	Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. Journal of Nuclear Medicine, 2007, 48, 100-7.	5.0	21
78	Molecular Imaging of the Dopaminergic System and its Association with Human Cognitive Function. Biological Psychiatry, 2006, 59, 898-907.	1.3	258
79	Chemical fate of the nicotinic acetylcholinergic radiotracer [123I]5-IA-85380 in baboon brain and plasma. Nuclear Medicine and Biology, 2006, 33, 549-554.	0.6	6
80	Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Annals of Neurology, 2006, 59, 174-177.	5.3	85
81	Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D1 receptor radioligand 11C-NNC 112 in humans. Journal of Nuclear Medicine, 2006, 47, 100-4.	5.0	16
82	PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. Journal of Nuclear Medicine, 2006, 47, 520-7.	5.0	135
83	Specific in vitro binding of (S,S)-[3H]MeNER to norepinephrine transporters. Synapse, 2005, 56, 100-104.	1.2	20
84	Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET. Neurolmage, 2005, 26, 1201-1210.	4.2	41
85	Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D 2 receptors using [ 123 I]epidepride SPET. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 644-654.	6.4	11
86	Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. Biological Psychiatry, 2004, 56, 95-100.	1.3	59
87	Dr. Kugaya and Colleagues Reply. American Journal of Psychiatry, 2004, 161, 2136-a-2136.	7.2	2
88	Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates. Nuclear Medicine Communications, 2004, 25, 737-742.	1.1	8
89	Quantification of nicotinic acetylcholine receptors in human brain using [1231]5-l-A-85380 SPET. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1620-1629.	6.4	45
90	Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [1231]5-I-A-85380. Synapse, 2003, 48, 116-122.	1.2	23

#	Article	IF	Citations
91	Cerebral benzodiazepine receptors in depressed patients measured with [123i]iomazenil SPECT. Biological Psychiatry, 2003, 54, 792-799.	1.3	57
92	Increase in Prefrontal Cortex Serotonin < sub > 2A < /sub > Receptors Following Estrogen Treatment in Postmenopausal Women. American Journal of Psychiatry, 2003, 160, 1522-1524.	7.2	195
93	Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities. Journal of Nuclear Medicine, 2003, 44, 512-9.	5.0	25
94	Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123I]5-I-A-85380 in healthy human subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 183-190.	6.4	56
95	Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research - Neuroimaging, 2001, 106, 81-93.	1.8	18
96	Measurement of plasma metabolites of (S)-5-[123I]iodo-3- (2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates. Nuclear Medicine and Biology, 2001, 28, 91-96.	0.6	29
97	Sex differences in [ <sup>123</sup> ]ĵ²â€€IT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse, 2001, 41, 275-284.	1.2	232
98	In vivo receptor imaging with PET and SPET-pitfalls in quantification. International Review of Psychiatry, 2001, 13, 34-39.	2.8	3
99	Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans. European Journal of Pharmacology, 2000, 387, 179-188.	3.5	57
100	Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Annals of Nuclear Medicine, 2000, 14, 1-9.	2.2	33
101	SPECT imaging with the D4 receptor antagonist L-750,667 in nonhuman primate brain. Nuclear Medicine and Biology, 2000, 27, 547-556.	0.6	12
102	SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biological Psychiatry, 2000, 47, 96-106.	1.3	161
103	Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations. Biological Psychiatry, 2000, 48, 801-812.	1.3	50
104	Effects of Vigabatrin on the GABAergic System as Determined by [1231]lomazenil SPECT and GABA MRS. Epilepsia, 1999, 40, 1433-1438.	5.1	38
105	Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. European Journal of Pharmacology, 1999, 368, 161-172.	3.5	41
106	Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models., 1999, 31, 178-185.		34
107	Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors. Synapse, 1999, 34, 290-304.	1.2	47
108	[1231]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Research - Neuroimaging, 1999, 91, 163-173.	1.8	45

#	Article	IF	CITATION
109	Assessment of affinities of beta-CIT, beta-CIT-FE, and beta-CIT-FP for monoamine transporters permanently expressed in cell lines. Nuclear Medicine and Biology, 1998, 25, 53-58.	0.6	31
110	Enhancement of [123I]?-CIT binding in the striatum with clomipramine: Is there a serotonin-dopamine interaction?. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 403-408.	2.1	12
111	Decrease of the Central Type Benzodiazepine Receptor in Cortical Tubers in a Patient With Tuberous Sclerosis. Clinical Nuclear Medicine, 1997, 22, 130-131.	1.3	6
112	Enhancement of $[123 \ l]^{\hat{l}^2}$ -CIT binding in the striatum with clomipramine: is there a serotonin-dopamine interaction?. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 403-408.	6.4	0
113	Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Molecular Brain Research, 1996, 39, 127-136.	2.3	32
114	Differential kinetics of [1231]?-CIT binding to dopamine and serotonin transporters. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 431-436.	2.1	33
115	Distribution of cocaine recognition sites in rat brain: In vitro and ex vivo autoradiography with [1251]RTI-55. Journal of Chemical Neuroanatomy, 1994, 7, 13-23.	2.1	24
116	Ontogeny of dopamine transporter mRNA expression in the rat brain. Molecular Brain Research, 1993, 19, 222-226.	2.3	37
117	Localization and ontogeny of cells expressing preprodynorphin mRNA in the rat cerebral cortex. Brain Research, 1991, 541, 41-49.	2.2	15
118	Regional distribution of the cells expressing glycine receptor $\hat{l}^2$ subunit mRNA in the rat brain. Brain Research, 1991, 560, 23-37.	2.2	75